Influenza and Other Respiratory Viruses

Article	Citations
	339
	82
Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study	74
Cross‐Reactive Antibody Responses to Coronaviruses Elicited by SARS‐CoV‐2 Infection or Vaccination	71
Issue Information	51
Issue Information	47
Comparative complete scheme and booster effectiveness of COVID‐19 vaccines in preventing SARS‐CoV‐2 infections with SARS‐CoV‐2 Omicron (BA.1) and Delta (B.1.617.2) variants: A case–case study based on	45
A novel household‐based patient outreach pilot program to boost late‐season influenza vaccination rates during the COVID‐19 pandemic	43
Meeting Report: Controlled Human Influenza Virus Infection Model Studies: Current Status and Future Directions for Innovation	42
COVID‐19 Vaccine Effectiveness Against Hospitalization in Older Adults, VEBIS Hospital Network, Europe, September 2024–May 2025	38
Next‐Generation Sequencing for Characterizing Respiratory Tract Virome and Improving Detection of Viral Pathogens in Children With Pneumonia	37
Infection‐induced seroconversion and seroprevalence of SARS‐CoV‐2 among a cohort of children and youth in Montreal, Canada	36
Effectiveness of the XBB.1.5 COVID‐19 Vaccines Against SARS‐CoV‐2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 t	36
Cost‐Effectiveness Analysis of a Maternal Vaccination Program Against Respiratory Syncytial Virus in Norway	33
SARS‐CoV‐2 infection rate in Antananarivo frontline health care workers, Madagascar	29
A comparative immune response to COVID‐19 vaccination between children and adults	28
No evidence for HPAI H5N1 2.3.4.4b incursion into Australia in 2022	27
Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post‐vaccination but persist for at least 6 months	27
EMARIS Conference 2023: Convergence of science, policy, and practice on acute respiratory infections in post COVID‐19 Eastern Mediterranean Region	27
Low prevalence of seasonal influenza viruses in Hong Kong, 2022	27
Antigenic Characterization of H1N1 Influenza Viruses That Circulated During the 2019–2020 Season in Philadelphia, Pennsylvania	26
Evaluating Bacillus Calmette–Guérin Polysaccharide Nucleic Acid as an Adjuvant for Influenza Vaccines in Mice	26
Avian Influenza Virus (H5N1) Was Not Detected Among Dairy Cattle and Farm Workers in Pakistan	26
Antibiotic prescription for outpatients with influenza and subsequent hospitalisation: A cohort study using insurance data	26
Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial	26

Issue Information	25
	24
Risk factors for infection with influenza A(H3N2) virus on a US university campus, October–November 2021	23
Correction to: The Respiratory Syncytial Virus Prefusion F Protein Vaccine Attenuates the Severity of RSV‐Associated Disease in Breakthrough Infections in Adults ≥60 Years of Age	23
Survival bias and declining mortality risk in long‐term COVID‐19 studies	23
Coronary and Cerebrovascular Events and Exacerbation of Existing Conditions After Laboratory‐Confirmed Influenza Infection Among US Veterans: A Self‐Controlled Case Series Study	23
SARS‐CoV‐2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era: Input for Future Response	23
Results from the second WHO external quality assessment for the molecular detection of respiratory syncytial virus, 2019–2020	21
Live‐attenuated influenza vaccine effectiveness against hospitalization in children aged 2–6 years, the first three seasons of the childhood influenza vaccination program in England, 2013/14–2015/16	21
Drug use and severe outcomes among adults hospitalized with influenza, 2016–2019	21
A review of policies and coverage of seasonal influenza vaccination programs in the WHO Eastern Mediterranean Region	21
Coinfection of Influenza A and B and Human OC43 Coronavirus in Normal Human Bronchial Epithelial Cells	21
Examining the Influenza A Virus Sialic Acid Binding Preference Predictions of a Sequence‐Based Convolutional Neural Network	20
In‐field detection and characterization of B/Victoria lineage deletion variant viruses causing early influenza activity and an outbreak in Louisiana, 2019	20
Descriptive Epidemiology of Travel and Non‐Travel Related SARS‐CoV‐2 Gamma (P.1/501Y.V3) Variant Cases in England, 2021	20
Bidirectional Evolution of SARS‐CoV‐2 Virus in Immunocompromised Hosts	19
Inno4Vac Workshop Report Part 2: RSV‐Controlled Human Infection Model (CHIM) Strain Selection and Immune Assays for RSV CHIM Studies, November 2021, MHRA, UK	19
A Strategic Framework of SARS‐CoV‐2 Genomic Surveillance in Bangladesh	19
Changing Epidemiological Pattern and Higher Disease Burden of Influenza in China, 2022 to 2025	19
Tracking Seasonal Influenza Trends in South Tyrol During 2022/2023 Using Genomic Surveillance Data	19
Long‐Distance Avian Migrants Fail to Bring 2.3.4.4b HPAI H5N1 Into Australia for a Second Year in a Row	18
Aetiological Fraction of Influenza, Respiratory Syncytial Virus and Other Respiratory Pathogens in Infants Aged < 1 Year Hospitalised With Respiratory and Non‐Respiratory Medical Illness in South A	18
An Overview of the H5N1 mRNA Vaccine Pipeline	18
Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain	18
Association between SARS‐CoV‐2 infections during pregnancy and preterm live birth	17
Influenza vaccine and subsequent development of zoster	17
Issue Information	17
Issue Information	17
Issue Information	17
Association between COVID‐19 and consistent mask wearing during contact with others outside the household—A nested case–control analysis, November 2020–October 2021	17
Issue Information	17
Acute respiratory infection emergency access in a tertiary care children hospital in Italy, prior and after the SARS‐CoV‐2 emergence	16
The burden of the coronavirus disease 2019 virus infection in Burkina Faso: Results from a World Health Organization UNITY population‐based, age‐stratified sero‐epidemiological investigation	16
Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network	16
Assessment of Influenza Severity in Bhutan by Using WHO Framework Pandemic Influenza Severity Assessment (PISA): An Implementation Research Study	16
Establishing Epidemic and Intensity Thresholds After a Major Change in Respiratory Virus Surveillance in Spain in 2020	16
Geographic Progression of Infant Respiratory Syncytial Virus Associated Bronchiolitis Across the United States Before and Since the Onset of COVID‐19: Results From Four Health Systems, 2015–2023	16
Declines in Human Rhinovirus, Coronavirus, Parainfluenza, and Adenovirus Infections During the COVID‐19 Pandemic: Evidence From Household‐Based Cohort Studies in Lima, Peru	15
Prevalence of Respiratory Viruses in Children With Acute Respiratory Infections in Shanghai, China, From 2013 to 2022	15
Two‐year trajectories of COVID‐19 symptoms and their association with illness perception: A prospective cohort study in Amsterdam, the Netherlands	15
Seasonal Influenza Vaccine 2021/2022 Provides Limited Cross Reactivity Against Contemporary Swine Influenza A Virus Strains in Spain	15
Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom	15
Disease Burden of RSV Infections and Bronchiolitis in Young Children (< 5 Years) in Primary Care and Emergency Departments: A Systematic Literature Review	15
	15
Age‐specific severity of severe acute respiratory syndrome coronavirus 2 in February 2020 to June 2021 in the Netherlands	15
Multi‐decade national cohort identifies adverse pregnancy and birth outcomes associated with acute respiratory illness hospitalisations during the influenza season	15
Detection of clade 2.3.4.4 highly pathogenic avian influenza H5 viruses in healthy wild birds in the Hadeji‐Nguru wetland, Nigeria 2022	15
Targeting Respiratory Viruses: The Efficacy of Intranasal mRNA Vaccination in Generating Protective Mucosal and Systemic Immunity Against Influenza A (H1N1)	15
Effectiveness of first and second COVID‐19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021–July 2022	14
Issue Information	14

BNT162b2 vaccination reduced infections and transmission in a COVID‐19 outbreak in a nursing home in Germany, 2021	14
Knowledge, attitudes, and practices towards seasonal influenza vaccination among pregnant women and healthcare workers: A cross‐sectional survey in Afghanistan	14
COVID‐19 vaccine effectiveness against hospitalization due to SARS‐CoV‐2: A test‐negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain	14
Domination of influenza vaccine virus strains in Hong Kong, 2021	13
Human Immune Response to Influenza Neuraminidase After Vaccination: A Systematic Review	13
Impact of COVID‐19 Nonpharmaceutical Interventions on Respiratory Syncytial Virus Infections in Hospitalized Children	13
Genomic Analysis and Tracking of SARS‐CoV‐2 Variants in Gwangju, South Korea, From 2020 to 2022	13
	13
Characterization of high pathogenicity avian influenza H5Nx viruses from a wild harbor seal and red foxes in Denmark, 2021 and 2022	13
Applying symptom dynamics to accurately predict influenza virus infection: An international multicenter influenza‐like illness surveillance study	13
Bridging Genomics and Clinical Medicine: RSVrecon Enhances RSV Surveillance With Automated Genotyping and Clinically Important Mutation Reporting	13
Issue Information	13
Relevance of comorbidities for main outcomes during different periods of the COVID‐19 pandemic	13
Bacterial and viral infections among adults hospitalized with COVID‐19, COVID‐NET, 14 states, March 2020–April 2022	12
High‐Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults	12
Issue Information	12
Consolidating Estimates of the Incubation Period for Omicron Subvariants From the Literature and Their Comparison to the Estimate From Taiwan: A Systematic Review and Meta‐Analysis, September 2024	12
Comparative hospitalization risk for SARS‐CoV‐2 Omicron and Delta variant infections, by variant predominance periods and patient‐level sequencing results, New York City, August 2021–January 2022	12
A Systematic Review of New, Enhanced Surveillance Systems and Methodologies for Zoonotic Influenza Viruses in Animals and Human–Animal Interface	12
Antiviral Effectiveness, Clinical Outcomes, and Artificial Intelligence Imaging Analysis for Hospitalized COVID‐19 Patients Receiving Antivirals	12
Symptoms Associated With Detection of Viral Versus Bacterial Pathogens in Outpatients With Lower Respiratory Infections	12
Coronaviruses Among Swine Workers in Northern Vietnam	12
Clinical symptoms of SARS‐CoV‐2 breakthrough infection during the Omicron period in relation to baseline immune status and booster vaccination—A prospective multicentre cohort of health professionals	12
BNT162b2 Versus mRNA‐1273 Vaccines: Comparative Analysis of Long‐Term Protection Against SARS‐CoV‐2 Infection and Severe COVID‐19 in Qatar	11
The Detection of Influenza Virus Before and During the COVID‐19 Pandemic in Cameroon	11
Epidemiologic and Virologic Characteristics of Influenza in Lao PDR, 2016–2023	11
Evaluating the Economic and Epidemiological Impact of RSV Hospitalizations in Southern Austria [Southern Austria Respiratory Syncytial Virus INpatient Investigation (ARNI Study)]	11
Respiratory viral detection in the plasma and cerebrospinal fluid (CSF) of young febrile infants	11
Rapid and Safe Neutralization Assay for Circulating H5N1 Influenza Virus in Dairy Cows	11
Enhancing Omicron Sublineage Neutralization: Insights From Bivalent and Monovalent COVID‐19 Booster Vaccines and Recent SARS‐CoV‐2 Omicron Variant Infections	11
Unveiling the Spectrum of Respiratory Syncytial Virus Disease in Adults: From Community to Hospital	11
Influenza surveillance systems using traditional and alternative sources of data: A scoping review	10
Incidence, hospitalization, and mortality in children aged 5 years and younger with respiratory syncytial virus‐related diseases: A systematic review and meta‐analysis	10
Inpatient burden of respiratory syncytial virus in children ≤2 years of age in Germany: A retrospective analysis of nationwide hospitalization data, 2019–2022	10
Excess All‐Cause Mortality by Age and Gender During the COVID‐19 Pandemic in the Federation of Bosnia and Herzegovina, Bosnia and Herzegovina: 2020–2022	10
SARS‐CoV‐2 Reverse Zoonosis Among Cats in China: A One Health Investigation	10
Issue Information	10
Strengthening Respiratory Virus Surveillance in Sub‐Saharan Africa: Integrated Epidemiological and Genomic Monitoring in Côte d'Ivoire	10
Inference of age‐dependent case‐fatality ratios for seasonal influenza virus subtypes A(H3N2) and A(H1N1)pdm09 and B lineages using data from the Netherlands	10
An Outbreak of Respiratory Viral Infections in a Professional Ice Hockey Team	10
Functional decline at 1 year in hospitalized elderly pneumonia with SARS‐CoV‐2 Omicron variant: Comparison with the ancestral strain and Alpha variant	10
Effectiveness of the 2023 Autumn XBB.1.5 COVID‐19 Booster During Summer 2024 in the EU/EEA: A VEBIS Electronic Health Record Network Study	10
Low Levels of Neutralizing Antibodies Against SARS‐CoV‐2 KP.3.1.1 and XEC in Serum From Seniors in May 2024	10
Mortality patterns among COVID‐19 patients in two Saudi hospitals: Demographics, etiology, and treatment	10
Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023–2024 Season	10
Developing a sampling methodology for timely reporting of population‐based COVID‐19‐associated hospitalization surveillance in the United States, COVID‐NET 2020–2021	10
Effect of planned school breaks on student absenteeism due to influenza‐like illness in school aged children—Oregon School District, Wisconsin September 2014–June 2019	9
	9
	9
Temporal Trends in Respiratory Infection Epidemics Among Pediatric Inpatients Throughout the Course of the COVID‐19 Pandemic From 2018 to 2023 in Fukushima Prefecture, Japan	9
Correction to “An Overview of the H5N1 mRNA Vaccine Pipeline”	9
	9
Transmissibility of severe acute respiratory syndrome coronavirus 2 among household contacts of coronavirus disease 2019‐positive patients: A community‐based study in India	9
Association of Monocyte Count With Lung Function and Exercise Capacity Among Hospitalized COVID‐19 Survivors: A 2‐Year Cohort Study	9
Transmission of SARS‐CoV‐2 in standardised first few X cases and household transmission investigations: A systematic review and meta‐analysis	9
	9
Nomenclature for Tracking of Genetic Variation of Seasonal Influenza Viruses	9
State and situation of avian influenza in the Eastern Mediterranean Region	9
Correction to ‘Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain’	8
Estimating the serial intervals of SARS‐CoV‐2 Omicron BA.4, BA.5, and BA.2.12.1 variants in Hong Kong	8
Feasibility of a Pilot Crowdsourced Syndromic and Virological Surveillance Platform for Respiratory Illness in South Africa, CoughWatchSA, 2022	8
Estimated mortality due to seasonal influenza in southeast of Iran, 2006/2007 to 2011/2012 influenza seasons	8
Clinical outcomes of COVID‐19 treated with remdesivir across the continuum of care	8
Anticoronavirus Isoquinoline Alkaloids: Unraveling the Secrets of Their Structure–Activity Relationship	8
Change in functional status associated with respiratory syncytial virus infection in hospitalized older adults	8
Role of research Laboratories in pandemic and epidemic response in the Eastern Mediterranean Region: Experiences from COVID‐19, avian influenza, and MERS‐CoV	8
Rapid assessment of case recruitment tools to inform integrated surveillance of influenza and other respiratory viruses in Eastern Mediterranean countries	8
Estimated Incidence Rate of Specific Types of Cardiovascular and Respiratory Hospitalizations Attributable to Respiratory Syncytial Virus Among Adults in Germany Between 2015 and 2019	8
Trends in Hospitalisations for Vaccine Preventable Respiratory Infections Following Emergency Department Presentations in New South Wales, Australia, 2012–2022	8
Investigating confounding in network‐based test‐negative design influenza vaccine effectiveness studies—Experience from the DRIVE project	7
Pronounced antibody elevation after SARS‐CoV‐2 BNT162b2 mRNA booster vaccination in nursing home residents	7
Influenza‐associated respiratory illness among five cohorts of pregnant women and their young infants (0–6 months), Bangladesh, 2013–2017	7
High Infection Risk Among Health Care Workers During the First SARS‐CoV‐2 Wave in Niamey, Niger	7
Modifiable in‐hospital factors for 12‐month global cognition, post‐traumatic stress disorder symptoms, and depression symptoms in adults hospitalized with COVID‐19	7
Longitudinal SARS‐CoV‐2 Antibody Response in Healthcare Workers: Benefit of Prior Infection and Heterologous Boosting on Anti‐Spike IgG Immunity	7
Cardiac Characteristics of Hospitalized Influenza Patients: An Interim Analysis From the FluHeart Study	7
Household transmission investigation: Design, reporting and critical appraisal	7
	7
Should We Vaccinate Healthcare Workers Against Respiratory Syncytial Virus?	7
Measures of Population Immunity Can Predict the Dominant Clade of Influenza A (H3N2) in the 2017–2018 Season and Reveal Age‐Associated Differences in Susceptibility and Antibody‐Binding Specificity	7

Influenza Epidemiology in Finland During and After the COVID‐19 Pandemic: Surveillance Data Analysis (2019–2024)	7
Enhanced safety surveillance of GSK's quadrivalent seasonal influenza vaccine in Germany and Spain (2021/2022 season) using an electronic patient‐reported outcome system for vaccine safety remote moni	7
Neutralizing and protective murine monoclonal antibodies to the hemagglutinin of influenza H5 clades 2.3.2.1 and 2.3.4.4	7
Incidence of Hospitalization due to Influenza‐Associated Severe Acute Respiratory Infection During 2010–2019 in Bangladesh	7
Changes in the Epidemiology of Influenza and Respiratory Syncytial Virus During 2020–2022 Relative to the Pre‐COVID‐19 Pandemic Period (2017–2020) From Systematic Sentinel Syndromic Surveillance in So	7
Issue Information	7
The Second Round of a Population‐Based Seroprevalence Study of Anti–SARS‐CoV‐2 Antibodies and COVID‐19 Vaccination Assessment in the Republika Srpska, Bosnia and Herzegovina	7
Performance of established disease severity scores in predicting severe outcomes among adults hospitalized with influenza—FluSurv‐NET, 2017–2018	7
SARS‐CoV‐2 Viral Load and Cytokine Dynamics Profile as Early Signatures of Long COVID Condition in Hospitalized Individuals	7
Rapid influenza molecular testing in secondary care and influenza surveillance in England: Any impact?	7
Estimating mortality associated with seasonal influenza among adults aged 65 years and above in China from 2011 to 2016: A systematic review and model analysis	7
	7
Seasonal respiratory virus circulation was diminished during the COVID‐19 pandemic	7
Sparse Evidence of Influenza C on US Dairy and Beef Cattle Farms	7
	7
	7
Neurologic Complications of Influenza and Potential Protective Vaccine Effects	7
Molecular Analysis of Human Respiratory Syncytial Virus Group B Strains Isolated in Kenya Before and During the Emergence of Pandemic Influenza A/H1N1	7
Human parainfluenza 2 & 4: Clinical and genetic epidemiology in the UK, 2013–2017, reveals distinct disease features and co‐circulating genomic subtypes	6
	6
Cover Image	6
Estimating SARS‐CoV‐2 infections and associated changes in COVID‐19 severity and fatality	6
Severe Neurological Complications With Influenza in Vietnamese Children	6
SARS‐CoV‐2 Infection Among Nursing Home Healthcare Workers: A Longitudinal Study in North‐Eastern Italy	6
Prevalence and Age at Diagnosis of Risk Factors for Severe Respiratory Syncytial Virus Disease Among US Adults: An Analysis of 2011–2020 NHANES Data	6
WHO's Investigations and Studies, Unity Studies: A global initiative creating equitable opportunities for enhanced surveillance, operational research, capacity building, and global knowledge sharing	6
Investigating the effects of population density of residence and rural/urban classification on rate of influenza‐like illness symptoms in England and Wales	6
Burden of Severe Disease Associated With Influenza, SARS‐CoV‐2 and RSV in Spain During the 2024–2025 Winter Season	6
Influenza Vaccine Effectiveness in Australia During 2017–2019	6
Evaluating COVID‐19 Transmission in a Series of Cases and Contacts in Three Municipalities of Colombia: Insights From the WHO First Few X Protocol, August 2020–January 2021	6
Transmissibility and severity of COVID‐19 in a humanitarian setting: First few X investigation of cases and contacts in Juba, South Sudan, 2020	6
Issue Information	6
Evaluating the Impact of Different Methods on the Timing and Duration of RSV Epidemics: Analysis of Surveillance Data From the GERi (Global Epidemiology of RSV in Hospitalized and Community Care) Stud	6
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1	6
Adverse Effects Related to Paediatric Influenza Vaccination and Its Influence on Vaccination Acceptability. The FLUTETRA Study: A Survey Conducted in the Region of Murcia, Spain	6
Association between population density of residence or rural/urban classification and rate of influenza‐like illness symptoms in England and Wales	6
Authors respond to Chan et al.	6
Issue Information	6
Sex differences in COVID‐19 symptom severity and trajectories among ambulatory adults	6
Low Levels of Neutralizing Antibodies to Influenza A (H5N1) and D Viruses Among Cattle and Cattle Workers on US Farms, 2024–2025	5
Impact of the COVID‐19 Pandemic on Influenza Circulation During the 2020/21 and 2021/22 Seasons, in Europe	5
Predictors of all‐cause mortality among patients hospitalized with influenza, respiratory syncytial virus, or SARS‐CoV‐2	5
Impact of Nirsevimab on RSV and Non‐RSV Severe Respiratory Infections in Hospitalized Infants	5
Immune Priming and the Risk of COVID‐19, Influenza, and Other Acute Respiratory Infections: Insights From an N3C Cohort	5
First Detection of Boosepivirus B1 in a Sick Yearling's Nasal Swab, Mexico	5
Technological Barriers to Routine Genomic Surveillance for Vaccine Development Against SARS‐CoV‐2 in Africa: A Systematic Review	5
Epidemiological Shifts in Children Respiratory Pathogens in Shenzhen, China: A Comparative Analysis Before and After the Relaxation of COVID‐19 Non‐Pharmaceutical Interventions	5
Severe viral respiratory infections in the pre‐COVID era: A 5‐year experience in two pediatric intensive care units in Italy	5
SARS‐CoV‐2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study	5
Persistent predominance of the Victoria lineage of influenza B virus during COVID‐19 epidemic in Nanchang, China	5
Correspondence About the Paper “Effectiveness of High‐Dose Influenza Vaccine Against Hospitalisations in Older Adults (FLUNITY‐HD): An Individual Level Pooled Analysis” by Niklas Dyrby Johansen et al.	5
Measuring respiratory syncytial virus infection severity in hospitalized children using the Pediatric Respiratory Syncytial Virus Electronic Severity and Outcome Rating System (PRESORS)	5
The epidemiological pattern of seasonal influenza in four sentinel sites in Iraq	5
Monitoring Influenza C and D Viruses in Patients With Respiratory Diseases in Japan, January 2018 to March 2023	5
Characteristics of Adults With Non‐Hospitalized Severe Respiratory Illness: Findings From a COVID‐19 Vaccine Effectiveness Evaluation in Kenya, 2022–2023	5
Lessons learned from identifying clusters of severe acute respiratory infections with influenza sentinel surveillance, Bangladesh, 2009–2020	5
No Evidence of Novel Respiratory Viruses on Two Texas Dairy Farms Before the H5N1 Avian Influenza Virus Epizootic	5
Issue Information	5
Modeling the impact of COVID‐19 nonpharmaceutical interventions on respiratory syncytial virus transmission in South Africa	5
Influenza Epidemiology and Vaccine Effectiveness Following Funded Influenza Vaccine in Queensland, Australia, 2022	5
Symptom‐based case definitions for COVID‐19: Time and geographical variations for detection at hospital admission among 260,000 patients	5
COVID‐19 Hospitalizations, Vaccine Uptake, Vaccination Guidelines, and Vaccine Availability in Six Middle‐Income Countries and Areas in Europe, May 2022–April 2024	5
Excess Respiratory Hospitalisations Associated with Influenza, Respiratory Syncytial Virus and SARS‐CoV‐2 in Singapore from 2015 to 2023	5
Absences, Symptoms and Respiratory Viruses in a Swiss School: Longitudinal Study With Serial Saliva Sampling	5
Nasal shedding of vaccine viruses after immunization with a Russian‐backbone live attenuated influenza vaccine in India	5
Evolution of Influenza A(H3N2) Viruses in Bhutan for Two Consecutive Years, 2022 and 2023	5
Internationally standardized respiratory viral load testing with limited resources: A derivative‐of‐care calibration strategy for SARS‐CoV‐2	5
Post‐Mortem Community Surveillance of COVID‐19: Implementation and Evaluation of a Pilot System in the Funeral Sector in England, UK, January 2021 to February 2022	5
The Asymptomatic Proportion of SARS‐CoV‐2 Omicron Variant Infections in Households: A Systematic Review	5
A nucleic acid amplification test‐based strategy does not help inform return to work for healthcare workers with COVID‐19	5
Effect of antipyretics on performance of influenza surveillance in Ghana	4
Issue Information	4
Shifts in Respiratory Virus Epidemiology on Reunion Island From 2017 to 2023: Impact of COVID‐19 Pandemic and Non‐Pharmaceutical Interventions	4
Nirsevimab Effectiveness Against RSV‐Related Hospitalisations in Children Under 24 Months: A Test‐Negative Case–Control Study in Portugal, 2024–2025	4
Impact of Real‐Time, On‐Demand Influenza and Respiratory Syncytial Virus Testing at Point‐of‐Care on Antibiotic Prescribing and Clinical Outcome in Pediatric Outpatients With Acute Respiratory Illness	4
Interactions among acute respiratory viruses in Beijing, Chongqing, Guangzhou, and Shanghai, China, 2009–2019	4
Issue Information	4
Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination	4
A phased strengthening of laboratory capacity in the Eastern Mediterranean Region during the COVID‐19 pandemic	4
Issue Information	4
Influenza vaccination uptake among at‐risk patients in Switzerland—The potential of national claims data for surveillance	4
The evaluation of an automated mariPOC SARS‐CoV‐2 antigen test compared to RT‐qPCR SARS‐CoV‐2 assay and comparison of its sensitivity in Delta‐ and Omicron‐variant samples	4
The Epidemiology, Phylogeny, and Strain Antigenicity of an Influenza A/H3N2 Virus Outbreak Among Vaccinated US Navy Midshipmen	4
Economic Impact of Respiratory Syncytial Virus Infections in Children Under 5 Years of Age Attending Primary Care in Italy: A Prospective Cohort Study in Two Regions	4
The association between ambient pollutants and influenza transmissibility: A nationwide study involving 30 provinces in China	4
Pilot of asymptomatic swabbing of humans following exposures to confirmed avian influenza A(H5) in avian species in England, 2021/2022	4
Evolution of seroprevalence to SARS‐CoV‐2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Cross‐sectional and longitudinal studies	4
Monitoring COVID‐19 vaccine effectiveness against COVID‐19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November	4
	4
SARS‐CoV‐2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February–December 2022	4
How Has the Disappearance of Influenza B/Yamagata Altered the Proportion of Influenza A and B Cases? Early Findings From Post‐COVID Pandemic Global Surveillance Data	4
Changes in Respiratory Syncytial Virus‐Associated Hospitalisations Epidemiology After Nirsevimab Introduction in Lyon, France	4
Antibody Response to Symptomatic Infection With SARS‐CoV‐2 Omicron Variant Viruses, December 2021–June 2022	4
Genomic Insights Into Respiratory Syncytial Virus Circulation Patterns and Neutralization by Anti‐F Monoclonal Antibodies in Panama (2018–2024)	4
The Need to Analyze Telogen Effluvium and Alopecia Areata Parallelly in Long COVID Studies	4